Skip to main content
PROTIA INC. logo

PROTIA INC. — Investor Relations & Filings

Ticker · 303360 ISIN · KR7303360002 KO Manufacturing
Open in API
Filings indexed 246 across all filing types
Latest filing 2019-05-30 Declaration of Voting R…
Country KR South Korea
Listing KO 303360

About PROTIA INC.

https://www.protia.co.kr/en/main

PROTIA INC. is an in-vitro diagnostics (IVD) company that develops, manufactures, and sells a wide range of diagnostic kits and instruments. The company is particularly known for its flagship product, PROTIA Allergy-Q, a multiplex allergy diagnostic kit for the quantitative determination of allergen-specific IgE. Its portfolio also includes point-of-care testing (POCT) solutions like the ImmuneCheck IgG kit, diagnostic tests for infectious and autoimmune diseases, cancer, and antibiotic susceptibility, as well as the ANITIA line for companion animal allergy testing. In addition to its product offerings, PROTIA provides comprehensive protein analysis services, including LC-MS/MS and characterization analysis, aiming to contribute to early disease prediction and diagnosis through innovative technology.

Recent filings

Filing Released Lang Actions
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) for ProteomeTech. It details the resolutions passed, specifically the re-election of directors and the approval of stock options. This falls under the category of Declaration of Voting Results, as it reports the outcome of shareholder voting at a general meeting.
2019-05-30 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to specific directors and employees, including exercise prices, vesting periods, and valuation methods. Since this document reports on the issuance of new rights (stock options) which affects the company's capital structure and potential future share issuance, it falls under the category of share/capital changes.
2019-05-30 Korean
기타주요경영사항(자율공시)
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure from ProteomeTech regarding the approval of a medical device (antibiotic susceptibility test reagent) by the Korea Medical Device Safety Information Service. It is categorized as a 'Major Management Matter' (자율공시) under Korean regulatory filing standards. Since it does not fit into specific categories like financial reports, dividends, or share transactions, and serves as a general regulatory announcement of a business development, it falls under the RNS (Regulatory Filings) category.
2019-05-24 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement regarding the results of a securities issuance (specifically convertible preferred shares via third-party allocation). It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2019-05-21 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a formal 'Notice of Extraordinary General Meeting' (주주총회소집공고) for ProteomeTech, dated May 15, 2019. It includes the meeting agenda, procedural details for shareholders, and management information regarding board activities and business outlook. This type of document is standard for proxy solicitation and shareholder meeting materials, which falls under the 'Proxy Solicitation & Information Statement' category.
2019-05-15 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) from a Korean company, ProteomeTech, detailing a decision for a third-party capital increase (유상증자결정). This type of filing is a standard regulatory disclosure in the Korean market regarding share issuance and capital changes. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the most accurate category for announcements regarding new share issues and capital structure changes.
2019-05-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.